SEC Form 4 · accession 0001209191-17-008201
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas P. Lynch
Officer — EVP. General Counsel & Sec.
Period of report
Feb 3, 2017
Accepted (ET)
Feb 7, 2017 · 6:49 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $4.10 | Feb 3, 2017 | A | 87,000 | A | — | Feb 2, 2027 | Common Stock | 87,000 | 87,000 | D |
| Stock OptionF2,F1 | $15.00 | Feb 3, 2017 | A | 43,500 | A | — | Feb 2, 2027 | Common Stock | 43,500 | 43,500 | D |
Explanation of responses
- F11/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/3/2017, so that all of the shares of the stock subject to the option shall be vested on 2/3/2021, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Issuer or any parent or subsidiary on each such date, as set forth in the applicable stock option grant notice and stock option agreement for such Reporting Person.
- F2Not Applicable